Ontology highlight
ABSTRACT: Background
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We performed a comprehensive review of phase 3 studies of tofacitinib 5 mg twice daily (BID) (approved dose in many countries) in patients with moderate to severe RA and inadequate response to prior disease-modifying antirheumatic drugs.Methods
A search of PubMed and ClinicalTrials.gov identified 5 studies: ORAL Solo (NCT00814307), ORAL Sync (NCT00856544), ORAL Standard (included adalimumab 40 mg once every 2 weeks; NCT00853385), ORAL Scan (NCT00847613), and ORAL Step (NCT00960440). Efficacy and safety data for tofacitinib 5 mg BID, placebo, and adalimumab were analyzed.Results
Across the 5 studies, 1216 patients received tofacitinib 5 mg BID, 681 received placeb
SUBMITTER: Bird P
PROVIDER: S-EPMC6445596 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature